MANNKIND CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.325 USD | +5.23% |
|
+3.22% | +18.82% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company has a low valuation given the cash flows generated by its activity.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.33 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +18.82% | 1.11B | C+ | ||
| -1.17% | 102B | B+ | ||
| +2.87% | 96.09B | B+ | ||
| +2.13% | 22.28B | B | ||
| -14.77% | 21.4B | B+ | ||
| -8.79% | 18.14B | A- | ||
| -39.98% | 17.02B | A- | ||
| -13.21% | 16.09B | B | ||
| +8.55% | 13.83B | C+ | ||
| +35.75% | 11.97B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MNKD Stock
- Ratings MannKind Corporation
